Certolizumab pegol in the treatment of Takayasu arteritis


Novikov P. I. , Smitienko I. O. , Sokolova M. V. , Alibaz-Oner F. , Kaymaz-Tahra S., Direskeneli H. , ...Daha Fazla

RHEUMATOLOGY, cilt.57, sa.12, ss.2101-2105, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Konu: 12
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1093/rheumatology/key197
  • Dergi Adı: RHEUMATOLOGY
  • Sayfa Sayıları: ss.2101-2105

Özet

Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).